Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes C-TIL051
- Development stage
- Unknown
- Lead developer
- AbelZeta, Inc.
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
C-TIL051 is an autologous tumor-infiltrating lymphocyte (TIL) therapy developed for the treatment of solid tumors, primarily non-small cell lung cancer (NSCLC). The therapy involves isolating immune cells (TILs) from a patient's surgically resected tumor, expanding them ex vivo, and then infusing them back into the patient. This approach aims to enhance the body's immune response against cancer by increasing the number of cytotoxic T cells that can recognize and destroy tumor cells. The mechanism of action is based on immunologic cytotoxicity and T lymphocyte replacement. Developed initially by Cellular Biomedicine Group (now AbelZeta Pharma), C-TIL051 is currently in Phase 1 clinical trials for NSCLC, including squamous subtypes and refractory/metastatic disease. It has also been considered for other solid tumors such as head and neck cancer, stomach cancer, esophageal cancer, and colorectal cancer[1][2][3][4][5][7].
- Other names
- autologous tumor-infiltrating lymphocytes C-TIL051
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes C-TIL051.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes C-TIL051.